Time for some commentary and review of ESMO highlights and lowlights from Paris

One of the fascinating aspects of the PARP inhibitor niche is how often the results across several different company trials have gone the same way more often than not.

This has been a rather unusual streak, let’s face it.

At some point I was half expecting the wheels to fall off the wagon and the trend to be bucked, to much consternation from outside observers.

It’s already starting to happen, although perhaps not in the way we might have anticipated.

After all, you can’t enroll patients willy nilly and expect to see a positive result every time because patient selection can and does matter over the long run.

Here, we discuss some of the emerging controversies coming out from ESMO…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by